PALI

Palisade Bio, Inc. Common Stock
Data: 2026-01-30
$1.49
Price
-6.21%
Change
$2.64
52W High
$0.53
52W Low

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Quick Stats
Jan 30, 2026

39.5

AI Score

SELL

1.21

Volume Ratio

Next Earnings

11

+ve Days (30d)

18

-ve Days (30d)

PALI Stock Summary

Last updated Jan 30, 2026

PALI is currently trading at $1.49, positioned above its 200-day moving average of $1.24, indicating a long-term uptrend. The stock has a 52-week range of $0.53 to $2.64.

Technical Analysis: The 50-day moving average stands at $1.97, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 37.279, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.14, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates PALI at 39.5/100 with a SELL recommendation.

PALI (Palisade Bio, Inc. Common Stock) Indicators

Last updated Jan 30, 2026

Indicator Value
RSI(14) 37.279
CMF (20) -0.14
ROC (10) -14.857
ADX (14) 11.899
Indicator Value
MACD (12,26,9) -0.099
AROONOSC (14) -100.0
WILLAMS %R (14) -92.857
MFI (14) 35.003
PALI Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

PALI Price vs Max Options Open Interest
PALI Max Change In Options Open Interest

PALI Options - Sort by Max open Interest (near term)

30th January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PALI Daily Out of Money Options - Sort by Max open Interest (near term)

30th January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PALI Daily In the Money Options - Sort by Max open Interest (near term)

30th January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PALI Most Active Options by Volume(near term)

30th January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Palisade Bio, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

PALI Moving Averages Analysis

Palisade Bio, Inc. Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jan 30, 2026

PALI (Palisade Bio, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Jan 30, 2026

Days MA
10 1.75
20 1.87
30 1.94
50 1.97
100 1.71
200 1.24

PALI Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 249.2 million
Earnings/Share ($) -2.07
Net Proft Margin (%) 0
Dividend/Share ($) --
EPS Estimate Current Year ($) -0.534
EPS Estimate Next Year ($) -0.23
WallStreet Target Price ($) 13.4
Most Recent Quarter